SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2018 / Cilt: 33 - Sayı: 2

Where Should Radiotherapy Stand in the Current era of Rectal Cancer Management?

Uğur SELEK
Duygu SEZEN
Yasemin BÖLÜKBAŞI
Nülifer KILIÇ DURANKUŞ
Pages
78–86
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Rectal cancer management can be defined as maximizing local tumor control and overall survival whilepreserving anal sphincter, bladder, and sexual functions or improving the quality of life with an overallreduction in morbidity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rectal cancer management can be defined as maximizing local tumor control and overall survival whilepreserving anal sphincter, bladder, and sexual functions or improving the quality of life with an overallreduction in morbidity.
📊
Key Findings & Data:Preoperative radiotherapy is the current standard for treatingpatients with high-risk rectal cancer owing to lower rates of local relapse and toxicity.
💡
Conclusion & Impact:Herein, we present a review of ongoing clinical trials in order to shed light on the currentdebates of standard approaches for treating rectal cancer.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Rectal cancer management can be defined as maximizing local tumor control and overall survival whilepreserving anal sphincter, bladder, and sexual functions or improving the quality of life with an overallreduction in morbidity. Appropriate preoperative or postoperative therapy is required to minimize therisks of both local and distant recurrence. Preoperative radiotherapy is the current standard for treatingpatients with high-risk rectal cancer owing to lower rates of local relapse and toxicity. Modern radiotherapy capabilities are well suited for any short- or long-course protocol with decreased toxicity in irradiated structures such as the small intestine, bladder, or femoral heads. As clinicians and researchers,we must aim to establish tailored treatments for these patients based on the most suitable evidence basedground in a multidisciplinary environment regarding the expectations of both our patients and teamphysicians. Herein, we present a review of ongoing clinical trials in order to shed light on the currentdebates of standard approaches for treating rectal cancer.

🔖

Cite This Article

SELEK, U., SEZEN, D., BÖLÜKBAŞI, Y., DURANKUŞ, N. K. (2022). Where Should Radiotherapy Stand in the Current era of Rectal Cancer Management?. Türk Onkoloji Dergisi, Cilt: 33 - Sayı: 2, 78–86. https://ajindex.com/articles/639239

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Merkel S, Mansmann U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001;16(5):298–304
  2. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2(8514):996–9
  3. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323–32
  4. Hermanek P, Merkel S, Fietkau R, Rödel C, Hohenberger W. Regional lymph node metastasis and locoregional recurrence of rectal carcinoma in the era of TME [corrected] surgery. Implications for treatment decisions. Int J Colorectal Dis 2010;25(3):359–68
  5. Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89(3):327–34
  6. Hall NR, Finan PJ, al-Jaberi T, Tsang CS, Brown SR, Dixon MF, et al. Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence? Dis Colon Rectum 1998;41(8):979–83
  7. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 1982;69(10):613–6
  8. Heald RJ. Total mesorectal excision. The new European gold standard. G Chir 1998;19(6-7):253–5
  9. Heald RJ. Surgical management of rectal cancer: a multidisciplinary approach to technical and technological advances. Br J Radiol 2005;78 Spec No 2:S128–30. 10.Leong AF. Selective total mesorectal excision for rectal cancer. Dis Colon Rectum 2000;43(9):1237–40. 11.Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SH, et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999;3(6):642–7. 12.MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341(8843):457–60. 13.Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudełko M, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72(1):15–24. 14.Marijnen CA, Nagtegaal ID, Kapiteijn E, Kranenbarg EK, Noordijk EM, van Krieken JH, et al. Radiotherapy does not compensate for positive resection